GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.
Read more at prnewswire.comAPR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/3D%20Graphics%20Concept%20Big%20Data%20Center%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
